---
layout: default
title: Colistimethate
parent: Model Prediction Only (L5)
nav_order: 221
evidence_level: L5
indication_count: 10
---

# Colistimethate
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **10** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# Colistimethate: From Gram-negative Bacterial Infections to Osteoarthritis

## One-Sentence Summary

Colistimethate is a polymyxin antibiotic that acts on the outer membrane of Gram-negative bacteria.
The TxGNN model predicts it may be effective for **osteoarthritis**, but there are currently **0 clinical trials** and **0 publications** supporting this direction.
This is a model-only prediction with no established pharmacological rationale.

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Gram-negative bacterial infections (polymyxin antibiotic; the Canadian licence record contains no indication text) |
| Predicted New Indication | Osteoarthritis |
| TxGNN Prediction Score | 97.78% |
| Evidence Level | L5 |
| Canada Market Status | ✓ Marketed |
| Number of DINs | 1 |
| Recommended Decision | Hold |

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the source records. Based on known information, colistimethate is a polymyxin-class antibiotic. Its efficacy in Gram-negative infections comes from its action on the bacterial outer membrane.

No established mechanistic link to osteoarthritis has been identified. The drug has no known effect on cartilage degradation or joint inflammation. The high score (97.78%) appears to reflect graph-neighbourhood similarity in the knowledge graph, not a pharmacological rationale.

The other top-ranked predictions show the same pattern. These include rheumatoid arthritis, gout, skeletal dysplasias such as pseudoachondroplasia and brachyolmia, and several hepatic conditions. Three hepatic predictions share an identical score (0.9627), which points to a graph artifact. None has any supporting trial or publication.

## Clinical Trial Evidence

Currently no related clinical trials registered.

## Literature Evidence

Currently no related literature available.

## Canada Market Information

| DIN | Product Name |
|---------|------|
| 2546639 | COLISTIMETHATE FOR INJECTION USP |

## Safety Considerations

Please refer to the package insert for safety information.

Colistimethate is known to carry nephrotoxicity and neurotoxicity concerns. These would be especially relevant in a chronic-use setting such as osteoarthritis or rheumatoid arthritis.

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The prediction is supported only by the TxGNN model score (Evidence Level L5, stage S0). There are no clinical trials or publications and no plausible mechanistic link. Colistimethate's nephrotoxicity and neurotoxicity make chronic use in a joint disease unattractive without strong supporting evidence.

**To proceed, the following is needed:**
- Mechanism of action data (for example from DrugBank) to test for any biologically plausible link to joint disease
- Preclinical evidence (in vitro or animal models) of an effect on cartilage degradation or joint inflammation
- The Health Canada package insert, to complete warnings, contraindications and approved indication review
- Route and dosing compatibility assessment, since no route information is available for the predicted indication
- Any prediction from the list that has independent literature or trial support, since none of the current top 10 does
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

